[Osteoporosis in the genome era].
Osteoporosis is a disease based on the low bone mineral density causing the bone fragility. Among the heterogeneous pathophysiology of this disease, age-related decrease of bone mass plays a key role. Osteoporosis is recognized as a multifactorial disease to which genetic and life-style risk factors contribute. Recently, genetic factors have been studied with polymorphisms of genes related to bone metabolism. However, the results have not been consistent and the systemic genome-wide approach has been awaited. Genetic analysis of osteoporosis will be utilized for the efficient diagnostic tool and the development of new drugs.
Hosoi
Takayuki
T
Endocrinology Section, Tokyo Metropolitan Geriatric Hospital.
D015519:Bone Density / Q000235:genetics; D015195:Drug Design; D015894:Genome, Human; D006801:Humans; D007378:Interleukins / Q000235:genetics; D010024:Osteoporosis / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics
D007378:Interleukins; D018167:Receptors, Calcitriol; D011960:Receptors, Estrogen